Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.
Drug: BTL-TML-COVID
Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.
Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.
Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.
Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Drug: Placebo
Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.
Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.
Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.
Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Inclusion Criteria:
- 40 years of age or older
- Provide written informed consent
- Have a SARS-COV-19 diagnostic test with positive results
Exclusion Criteria:
- Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
- Subjects currently hospitalized
- Subjects who have received a COVID vaccination
- Subjects with a diagnosis of immunodeficiency
Intermountain Clinical Reserach
Draper, Utah, United States